Photodynamic therapy and Acyclovir in the treatment of recurrent herpes labialis: A controlled randomized clinical trial

Photodiagnosis Photodyn Ther. 2021 Mar:33:102093. doi: 10.1016/j.pdpdt.2020.102093. Epub 2020 Nov 16.

Abstract

Background: Herpes Simplex Virus Type 1 (HSV-1) is one of the most widespread infections that can effect the orofacial region. Recurrent infection is considered a life-long oral health problem, leading to pain, discomfort, and social restriction due to esthetic features when active. Effective therapies are needed. This study aimed to compare photodynamic therapy (PDT), Topical Acyclovir (AC), and the association of both in the healing process and self-reported symptomologies of HSV-1 recurrences.

Methods: Patients were randomly assigned into 3 groups (n = 25): PDT (low-power laser, 660 nm, 40 mW, 120 J/cm2, 4.8 J, 120 s per point) and methylene blue (0.005 %) as photosensitizer; AC (5%); PDT + AC.Data concerning lesion size, healing time, and self-reported healing parameters, such as pain, tingling, and edema were taken every day up to complete healing for all studied groups.

Results: There was no significant difference in healing time and pain between groups. AC group showed a significant minor reduction of the lesion compared to the AC-PDT group on day 1. Regarding edema and tingling, the comparison of treatments showed a statistical difference only on day 1, where PDT showed better results.

Conclusion: With all the limitations of this study, it can be concluded that only on day 1 PDT showed positive effects in the treatment of herpes lesions in comparison to AC.

Keywords: Acyclovir; Herpes simplex; Laser; Methylene blue; Photodynamic therapy.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acyclovir / therapeutic use
  • Herpes Labialis* / drug therapy
  • Herpesvirus 1, Human*
  • Humans
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Recurrence

Substances

  • Photosensitizing Agents
  • Acyclovir